Therapy Areas: Cardiovascular
Saghmos Therapeutics Issued US Patent for ST-62516 for the Reduction of Kidney Injury in Patients with Chronic Kidney Disease Undergoing Contrast Procedures
18 November 2021 - - US-based biopharmaceutical company Saghmos Therapeutics, Inc has been issued a US patent for its lead product, ST-62516 (trimetazidine), the company said.

US Patent No. 11,123,345 provides exclusivity through 2037, with broad claims for the reduction of kidney injury in patients with chronic kidney disease undergoing contrast procedures.

Saghmos plans to begin a Phase 3 study of ST-62516 (trimetazidine) for the reduction of cardiorenal complications associated with Contrast-induced Kidney Injury in patients with CKD undergoing contrast procedures.

Trimetazidine is a mitochondrial metabolic modulator with clinical evidence of cardiorenal benefits, as well as favorable safety and tolerability shown in numerous published studies.

CIKI is an emerging public health problem, with increased risk of death, heart attacks, heart failure, prolonged hospitalization, and kidney failure leading to need for dialysis.

CIKI and associated complications result in billions of dollars in annual healthcare costs, and there are no FDA-approved drugs for this condition.

CIKI has a disproportionate impact on African Americans, with 3.4-fold higher prevalence of End Stage Renal Disease requiring dialysis. "ST-62516 will have broad societal impact by helping achieve health equity," said Anna Kazanchyan, M.D.

Saghmos Therapeutics is a privately held biopharmaceutical company whose mission is to develop innovative therapies for life-threatening cardiovascular and renal diseases with unmet medical need.